DAF
0.016
60%
ATC
0.001
-50%
FAU
0.009
50%
ARV
0.003
-25%
M2M
0.009
50%
CHM
0.015
-25%
DXN
0.39
41.8%
EPN
0.022
-24.1%
NXL
1.915
34.4%
RWL
0.15
-21.1%
ARO
0.004
33.3%
ERE
0.012
-20%
C7A
0.004
33.3%
FIN
0.004
-20%
RKB
0.004
33.3%
KGN
3.67
-18.6%
ABE
0.027
28.6%
IRD
0.009
-18.2%
AUQ
0.047
27%
SP3
0.009
-18.2%
PKY
0.043
26.5%
CDE
0.005
-16.7%
ACU
0.13
23.8%
ENL
0.005
-16.7%
AXN
0.033
22.2%
RLG
0.005
-16.7%
COY
0.006
20%
WIN
0.015
-16.7%
ECS
0.006
20%
ALM
0.011
-15.4%
ESR
0.036
20%
AEV
0.006
-14.3%
GTN
0.24
20%
CRR
0.006
-14.3%
RGL
0.012
20%
UNT
0.006
-14.3%
WRX
0.024
20%
HMG
0.225
-13.5%
ZEU
0.006
20%
NPM
0.013
-13.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PharmAust (ASX:PAA): Extension study begins

Clinical-stage biotechnology company, PharmAust (ASX:PAA), announces that the first patient has been dosed in the Open-Label Extension study at Calvary Health Care Bethlehem, which will investigate the long-term safety, tolerability and efficacy of monepantel in patients with Motor Neurone Disease.

ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02772313-6A1193834